Dr. Ansell Discusses the Role of PD-1 Blockade in Lymphoma

Video

In Partnership With:

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the role of PD-1 blockade in lymphoma.

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the role of PD-1 blockade in lymphoma.

Ansell says that the field is still working to understand the role of PD-1 blockade compared to antibody drug conjugates (ADCs) in lymphoma. In an attempt to answer this, there are currently trials in the relapsed/refractory setting where patients are being randomized to a PD-1 inhibitor or an ADC. Additionally, there are multiple trials utilizing these agents as upfront therapy, as well as in combination in the frontline, Ansell says.

There are opportunities for PD-1 blockade to make a home for itself in lymphoma. For example, elderly patients with Hodgkin lymphoma do not tolerate chemotherapy well, so using the ADC brentuximab vedotin (Adcetris) in combination with a PD-1 inhibitor has been quite promising as an alternative, Ansell explains.

Currently, pembrolizumab (Keytruda) and nivolumab (Opdivo) are FDA approved as single agents for the treatment of patients with Hodgkin lymphoma. Nivolumab is indicated for patients who have relapsed or progressed after autologous hematopoietic stem cell transplantation and posttransplantation brentuximab vedotin. Pembrolizumab was approved in March 2017 for the treatment of adult and pediatric patients who are refractory or have relapsed after 3 or more lines of therapy.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD